AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
阿斯利康阿斯利康(US:AZN) WSJ·2026-09-14 14:02

核心观点 - Etcamah的试验结果公布于美国批准该药物用于检测到特定突变的晚期乳腺癌之后一周 [1] 药物审批与进展 - 美国已批准该药物用于检测到特定突变的晚期乳腺癌 [1]

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial - Reportify